Einvestment Fund: “COVID-19 Vaccine-Driven Stocks Surge as Vaccine Developers Approach The Final Stage of Testing”

LISBON, PORTUGAL – Media OutReach – 13 October 2020 – �Einvestment Fund has reported the
continued growth of COVID-19 vaccine-driven stocks. This occurred after the leading global biotech firms have
finally come to the start of crucial late-stage trials of their experimental
coronavirus vaccine. 

The pharmaceutical
sector offers tremendous investment opportunities. Today it is the
second-largest segment of the US stock market by capitalization – about $ 4
trillion, analysts at Einvestment say. Recently, the health problem’s urgency
has significantly increased — the pandemics such as COVID-19, the growth of
oncological and hereditary diseases, diabetes, obesity, etc. are creating ever
more significant threats to humanity.

This growth is reflected
in an increase in stocks’ value, offering investors exceptional opportunities
for long-term capital appreciation. Once the long-awaited coronavirus vaccine
is in place, and the world begins to return to normal, monetary authorities may
change attitudes towards economic incentives. As for today’s situation at
Einvestment, the average gain of three vaccine-sensitive
positions in the investment portfolio exceeded
92% since June 2020
when the fund managers entered the vaccine rally.

Pfizer and Moderna
officials stated they should know before December whether their vaccines are
safe and effective. Still, the WHO and global government officials do not
expect any serum to be commercially accessible until next year.

The Health
Care sector’s share of positions in the fund
portfolio now exceeds 8%. In the words of
Managing Director, Peter Derksen: “We
hold significant share of Health Care positions in the investment portfolio,
and in early June of this year we allocated 2.8% of AUM to Biotech companies engaged
in vaccine development”. Biotech, as
well as the AI & Robotics sector, lead the “Top Gainers of 2020” list in the fund’s portfolio as of
Q4 2020. 

Einvestment’s technology-driven approach is
tailored to continue improving fund’s
performance and accelerating the market value growth of assets under management. Before allocating the funds to any assets, Einvestment experts initiate
an in-depth research process to develop a transparent framework of risks, opportunities,
goals, and deadlines. The fund’s segregated investment portfolios are
loaded with the appropriate mix of assets to ensure exposure to trending
sectors and most promising assets.